News
NVO
50.84
+4.24%
2.07
Microsoft Parachuting 6,000 AI Engineers into Global Clients as Part of New $2.5B AI Subsidiary
TipRanks · 2h ago
Ascendis Pharma: Behind The Stock Surge
Seeking Alpha · 2h ago
Novo reportedly seeking discounts from suppliers to cut costs
Seeking Alpha · 3h ago
Microsoft launches firm to help companies adopt AI with $2.5 billion
Reuters · 3h ago
Why Medicare Isn't a Game Changer for Weight-Loss Drugmakers -- Heard on the Street
The Wall Street Journal · 7h ago
Novo Nordisk (NVO) Stock Looks Below Fair Value On a 36% Slide
Simply Wall St · 17h ago
Moderately bullish activity in Novo Nordisk with shares up 1.51%
TipRanks · 21h ago
Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?
Barchart · 1d ago
Medicare opens access to GLP-1 weight-loss drugs
Seeking Alpha · 1d ago
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
NASDAQ · 1d ago
NOVO NORDISK - MEDICARE GLP-1 BRIDGE PROGRAM FOR WEGOVY RUNS THROUGH END OF 2027
Reuters · 1d ago
Novo Nordisk Stock (NVO) Rises as Medicare Starts Covering Obesity Drugs
TipRanks · 1d ago
EXPLAINER-Who qualifies for Medicare's new $50 weight-loss drug program and what are the concerns?
Reuters · 1d ago
ANALYSIS-Older Americans left out of costly GLP-1 craze expected to flock to new program
Reuters · 1d ago
The Latest Senior-Citizen Special Is Here: Cheap Weight-Loss Drugs
The Wall Street Journal · 1d ago
Like My Stock Portfolio, My Bullish Options Portfolio Crushed The Benchmarks
Seeking Alpha · 1d ago
Building A $100,000 Dividend Portfolio With SCHD And July's Top High-Yield Picks
Seeking Alpha · 1d ago
Medicare GLP-1 Bridge Program Will Pay for Novo, Lilly Drugs
Barron‘s · 1d ago
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Seeking Alpha · 1d ago
BRIEF-Shantha Biologics Entered Into Outsourcing Agreement With Novo Nordisk To Provide Cartridge Fill-Finish Manufacturing Services In India
Reuters · 2d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.